Ghandi Narges, Rashidi Atiyeh, Saberi Fatemeh, Abedini Robabeh, Tootoonchi Nasim, Babaie Hanie
Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Cosmet Dermatol. 2025 Aug;24(8):e70367. doi: 10.1111/jocd.70367.
Alopecia areata (AA) is an autoimmune condition resulting in hair loss, sometimes just in small patches but occasionally across larger areas like the entire scalp. For localized AA, treatments often involve injecting corticosteroids, such as triamcinolone acetonide (TrA), directly into the affected areas. Methotrexate (MTX), a drug known for its ability to suppress immune responses, has also been considered as an alternative. However, there has not been much research directly comparing these two treatments.
This study involved 40 individuals with localized AA. These patients were divided into two groups: one received TrA injections, and the other was given MTX. Both groups were treated once a month for 3 months. We tracked their progress using the Severity of Alopecia Tool (SALT) over 6 months. Their trichoscopic findings, adverse effects, and satisfaction with treatment were also documented.
Cases receiving TrA showed strong improvements, with their SALT scores dropping by an average of 54.36%, which meant significant hair regrowth. In contrast, the MTX group saw their scores worsen by 54.6%, meaning losing more hair. For trichoscopic changes, both groups showed some progress, but only the reduction in black dots in the MTX group was statistically significant. Side effects like mild redness or pigmentation changes were uncommon and similar for both groups. When asked how satisfied they were, patients who received TrA gave a much higher score:7.1 out of 10 compared to 4.9 for MTX.
According to our results, TrA outperformed MTX in treating localized AA, both in terms of hair regrowth and patient satisfaction. While MTX may have potential as a therapy, its inconsistent performance in this study suggests it is not ready to be a primary option for localized AA. Future research is needed to explore whether adjusting doses or combining it with other treatments could result in better outcomes.
斑秃(AA)是一种自身免疫性疾病,会导致脱发,有时只是小块脱发,但偶尔也会累及较大区域,如整个头皮。对于局限性斑秃,治疗通常包括将皮质类固醇,如曲安奈德(TrA),直接注射到受影响的区域。甲氨蝶呤(MTX),一种以抑制免疫反应能力而闻名的药物,也被视为一种替代疗法。然而,直接比较这两种治疗方法的研究并不多。
本研究纳入了40名局限性斑秃患者。这些患者被分为两组:一组接受TrA注射,另一组给予MTX。两组均每月治疗一次,共治疗3个月。我们使用脱发严重程度工具(SALT)在6个月内跟踪他们的进展。还记录了他们的毛发镜检查结果、不良反应和对治疗的满意度。
接受TrA治疗的病例有明显改善,其SALT评分平均下降了54.36%,这意味着有显著的毛发再生。相比之下,MTX组的评分恶化了54.6%,意味着脱发更多。对于毛发镜检查变化,两组都有一些进展,但只有MTX组黑点的减少具有统计学意义。轻度发红或色素沉着变化等副作用并不常见,两组相似。当被问及满意度时,接受TrA治疗的患者给出了更高的分数:10分制中为7.1分,而MTX组为4.9分。
根据我们的结果,在治疗局限性斑秃方面,TrA在毛发再生和患者满意度方面均优于MTX。虽然MTX可能有作为一种治疗方法的潜力,但其在本研究中的表现不一致表明它还不适宜作为局限性斑秃的主要选择。需要进一步的研究来探索调整剂量或与其他治疗方法联合使用是否能产生更好的效果。